This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Alector +2.08%
CrowdStrike -3.97%
Dianthus Therapeutics, Inc. -2.06%
Rivian Automotive +1.25%
SolarEdge Technologies, Inc. -0.19%

Alector

ALEC

2.45

+2.08%

CrowdStrike

CRWD

379.02

-3.97%

Dianthus Therapeutics, Inc.

DNTH

89.77

-2.06%

Rivian Automotive

RIVN

15.43

+1.25%

SolarEdge Technologies, Inc.

SEDG

41.76

-0.19%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Morgan Stanley analyst Keith Weiss upgraded CrowdStrike Holdings (NASDAQ:CRWD) from Equal-Weight to Overweight and raised the price target from $487 to $510. CrowdStrike shares closed at $434.13 on Monday. See how other analysts view this stock.
  • BTIG analyst Thomas Shrader upgraded Alector Inc (NASDAQ:ALEC) from Neutral to Buy and announced a $6 price target. Alector shares closed at $2.19 on Monday. See how other analysts view this stock.
  • TD Cowen analyst Itay Michaeli upgraded Rivian Automotive Inc (NASDAQ:RIVN) from Hold to Buy and raised the price target from $17 to $20. Rivian Automotive shares closed at $15.87 on Monday. See how other analysts view this stock.
  • B of A Securities analyst Julien Dumoulin-Smith upgraded Solaredge Technologies Inc (NASDAQ:SEDG) from Underperform to Neutral and raised the price target from $17 to $40. SolarEdge shares closed at $34.59 on Monday. See how other analysts view this stock.
  • Raymond James analyst Steven Seedhouse upgraded Dianthus Therapeutics Inc (NASDAQ:DNTH) from Outperform to Strong Buy and raised the price target from $63 to $123. Dianthus Therapeutics shares closed at $79.23 on Monday. See how other analysts view this stock.

Considering buying CRWD stock? Here’s what analysts think:

Photo via Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.